Telix Pharmaceuticals Limited American Depositary Receipt (TLX)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
All You Need to Know About Telix Pharmaceuticals Limited (TLX) Rating Upgrade to Buy
Telix Pharmaceuticals Limited (TLX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Telix Shares May Gain on the Distribution Deal With Cardinal Health
TLX rolls out a new e-commerce platform connecting users to top retail pharmacies, aiming to boost savings, improve access, and expand its digital health services.
Telix Pharmaceuticals Gets FDA Approval for Prostate Cancer Screening Agent
Shares of Australia-based Telix Pharmaceuticals (TLX) rose 6% Friday as the U.S. Food and Drug Administration (FDA) approved the biopharma firm's agent for use in tests to screen for prostate cancer.
Telix Pharmaceuticals Limited American Depositary Receipt (TLX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Telix Pharmaceuticals Limited American Depositary Receipt ever had a stock split?
Telix Pharmaceuticals Limited American Depositary Receipt Profile
| Biotechnology Industry | Healthcare Sector | Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, CEO | NASDAQ (NGS) Exchange | US87961M1053 ISIN |
| AU Country | - Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Telix Pharmaceuticals Limited is a biopharmaceutical company that is in the commercial stage, with a primary focus on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. These products are designed for managing and treating cancer and rare diseases. The company operates across multiple regions, including Australia, Belgium, Japan, Switzerland, and the United States. Founded in 2015, Telix Pharmaceuticals has its headquarters located in North Melbourne, Australia. Through its innovative research and development activities, the company aims to bring new solutions to the medical field, particularly in oncology and radiopharmacy.
Products and Services
- Illuccix
This is a diagnostic and therapeutic product designed for the treatment of prostate cancer, showcasing Telix Pharmaceuticals’ contribution towards improving prostate cancer care.
- TLX66-CDx (for imaging osteomyelitis)
A diagnostic radiopharmaceutical specifically developed for imaging osteomyelitis, aiding in the diagnosis and management of this complex bone infection.
- TLX591
A radio antibody-drug conjugate aimed at treating prostate cancer, representing an innovative approach in targeting cancer cells directly with radiotherapy.
- TLX250-CDx
Designed for the treatment and diagnosis of renal (kidney) cancer, TLX250-CDx brings new hope for patients with this type of cancer through targeted therapy and diagnostics.
- TLX101-CDx
This product candidate is focused on brain (glioma) cancer, offering a potential new way to treat and diagnose one of the most challenging forms of cancer.
- TLX66-CDx (for bone marrow conditioning)
Developed for bone marrow conditioning, this radiopharmaceutical aims to prepare patients for hematopoietic cell transplantation, an important treatment for various blood disorders.
- TLX300-CDx
A product candidate for the treatment and diagnosis of soft tissue sarcoma, TLX300-CDx represents a targeted approach to managing this type of cancer.
- TLX250
For the treatment of clear cell renal cell carcinoma, TLX250 stands out as a therapeutic development, offering a new avenue for treating kidney cancer.
- TLX101
Specifically being developed for the treatment of glioblastoma (brain cancer), TLX101 is part of Telix Pharmaceuticals’ efforts to combat one of the most aggressive cancers.
- TLX66 (for bone marrow conditioning)
Another treatment avenue for bone marrow conditioning, highlighting Telix Pharmaceuticals’ commitment to supporting patients undergoing hematopoietic cell transplantation.
- TLX300
Aimed at treating soft tissue sarcoma, TLX300 focuses on delivering targeted therapy for this challenging cancer, potentially improving patient outcomes.
- TLX592
A prostate cancer therapy candidate designed for targeted alpha therapy, TLX592 is an example of the company’s innovative work in developing new cancer treatments.
Contact Information
